GuidelinePractical radiation oncology
Radiation Therapy for Gastric Cancer: An ASTRO Clinical Practice Guideline.
Guideline in Practical radiation oncology. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
21 authors.
Funding
Abstract
purposeThis guideline provides evidence-based recommendations addressing the indications for radiation therapy (RT) for gastric cancer in a variety of clinical settings, ranging from patients with resectable locoregional disease to metastatic and symptomatic disease.
methodsThe American Society for Radiation Oncology convened a task force to address 3 key questions: (1) indications for and timing of RT for patients with resectable and nonmetastatic gastric cancer; (2) indications for and timing of RT in patients with unresectable locoregional disease, oligometastases, and/or requiring palliation; and (3) appropriate RT dose-fractionation regimens, target volumes, and techniques in these clinical settings. Recommendations are based on a systematic literature review and were created using a predefined consensus-based methodology with a system for grading evidence quality and recommendation strength.
resultsMultidisciplinary evaluation and decision-making are recommended for all patients. For patients with cT2-4 and/or N+ resectable gastric cancer, perioperative chemotherapy is recommended, preferably FLOT (5-fluorouracil, leucovorin, oxaliplatin, and docetaxel). Recently, perioperative durvalumab and FLOT has shown a significant improvement in event-free survival versus FLOT only for patients with resectable disease and is now being adopted as a standard of care. Preoperative chemoradiation is recommended for patients who are not candidates for perioperative chemotherapy and conditionally recommended if there is concern for a margin-positive (R1) or incomplete (R2) resection. Postoperative chemoradiation is conditionally recommended for patients who are not candidates for perioperative or postoperative chemotherapy or if a suboptimal resection was done (eg, <D2 or R1-R2) for those who proceeded directly to surgery. Definitive chemoradiation may provide durable control for nonmetastatic patients who are inoperable either at initial diagnosis or at the time of locoregional recurrence. For patients with oligometastatic gastric cancer, metastasis-directed therapy along with systemic therapy is conditionally recommended. Palliative RT is efficacious for patients with bleeding, pain, and obstruction. Target coverage goals and dose guidance for normal tissues are provided.
conclusionsThese evidence-based recommendations guide clinical practice on the use of RT for gastric cancer. Future studies will further refine the indications and role of RT in the management of these patients.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.